The High Performing designation is the highest award a hospital can earn from U.S. News and World Report’s national rankings for hospitals providing maternity care. The annual evaluation is designed to assist expectant parents in making informed decisions about where to receive maternity care.
Cutting edge findings from the Children’s Minnesota Cancer and Blood Disorders research team and collaborators show variants in the deep intronic (noncoding) region of DICER1 may increase risk for tumor development in kids and young adults.
There are two new FDA-approved options to prevent respiratory syncytial virus (RSV) in infants: a maternal RSV vaccine (Abrysvo) and a monoclonal antibody (nirsevimab; Beyfortus). Both options provide passive immunity to infants and prevent hospitalization due to RSV infection.
Children’s Minnesota is pleased to announce that Katie Greenwood, MD, FAAP; Jennifer Hess, DO, MS, MPH; Megan Hilgers, MD; and Chelsea Self, MD, have joined the expanding cancer and blood disorders program.
Children’s Minnesota announced that Dr. Tom George, system medical director of neonatology, has been named the organization’s first holder of the newly established Sit Investment Associates Chair in Neonatology following a generous $2 million gift from the Minneapolis-based investment firm.
Children’s Minnesota is thrilled to announce Becker’s Hospital Review recognized the organization’s neurosurgery program on its list of 70 hospitals and health systems with spine and neuroscience programs to know in 2023.
The Health Justice Award recognizes organizations that have successfully implemented a program or intervention to reduce health disparities. Children's Minnesota's health equity team was recognized for championing community-based vaccine clinics for children and families.
The Health Equity team at Children’s Minnesota has been honored as a Top Finalist for the 2023 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity by The Joint Commission and Kaiser Permanente.
The CDC estimates that consistently one-fifth of newly diagnosed people with HIV in the U.S. annually are adolescents and young adults. Dr. Angela Kade Goepferd, chief education officer and medical director of the Gender Health program, and Dr. Katy Miller, medical director of the adolescent health program, share their thoughts about how to educate young patients to prevent STIs and stay safe.
A new antibody-drug conjugate (ADC) that targets B-cell acute lymphoblastic leukemia (B-ALL) is showing early promise in the fight against childhood leukemia. ALL is a cancer that involves the white blood cells of the bone marrow. It is the most common leukemia diagnosed in children and young adults.